Development of resistance to nalidixic acid and the fluoroquinolones after the introduction of norfloxacin and ofloxacin
about
Ofloxacin compared with chloramphenicol in the management of external ocular infectionEmergence of fluoroquinolone-resistant Escherichia coli at a cancer center.Genetic characterization of highly fluoroquinolone-resistant clinical Escherichia coli strains from China: role of acrR mutations.Rufloxacin once daily versus ofloxacin twice daily for treatment of complicated cystitis and upper urinary tract infections. Italian Multicentre UTI Rufloxacin Group.Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infectionsMolecular epidemiology of fluoroquinolone-resistant Escherichia coli bloodstream isolates from patients admitted to European cancer centers.Comparison of ofloxacin, gentamicin, and tobramycin concentrations in tears and in vitro MICs for 90% of test organisms.Increasing rates of in vitro resistance to ciprofloxacin and norfloxacin in isolates from urine specimensCharacterization of fluoroquinolone-resistant mutants of escherichia coli selected in vitro.Susceptibilities of ampicillin-resistant strains of Salmonella other than S. typhi to 10 antimicrobial agentsReduced susceptibilities of Shigella sonnei strains isolated from patients with dysentery to fluoroquinolones.Association with prior fluoroquinolone therapy of widespread ciprofloxacin resistance among gram-negative isolates in a Veterans Affairs medical center.Persistence mechanisms in Pseudomonas aeruginosa from cystic fibrosis patients undergoing ciprofloxacin therapy.Use of ciprofloxacin versus use of aminoglycosides for therapy of complicated urinary tract infection: prospective, randomized clinical and pharmacokinetic studyTopical ofloxacin compared with gentamicin in the treatment of external ocular infection. Ofloxacin Study Group.A review of the antimicrobial activity of the fluoroquinolones.Prospects for new antibiotics: a molecule-centered perspective.Quinolone antimicrobial agents: adverse effects and bacterial resistance.Exploration of fluoroquinolone resistance in Streptococcus pyogenes: comparative structure analysis of wild-type and mutant DNA gyrase.Quinolone resistance in clinical isolates of Serratia marcescensQuinolone resistance in Pseudomonas aeruginosa and Staphylococcus aureus. Development during therapy and clinical significance.Avoiding fluoroquinolone resistance. Strategies for primary care practice.[How can we protect against broad-band pathogens? The situation with quinolone resistance]In vitro antimicrobial activity of a new series of 1,4-naphthoquinones.Isolation of fluoroquinolone-resistant Escherichia coli and Klebsiella pneumoniae from an infected Hickman catheter.Impact of a fluoroquinolone formulary change on acquisition of quinolone-resistant gram-negative bacilli.Prevalence of fluoroquinolone resistance in Europe. Study Group 'Bacterial Resistance' of the Paul-Ehrlich-Society for Chemotherapy e. V.Susceptibility of clinical bacterial isolates to ciprofloxacin in the United States.[Fluoroquinolone carboxylic acids: is research on the development of resistance becoming invalidated?]Antibiotic resistance of Escherichia coli in fecal samples of healthy people in two different areas in an industrialized country.Increasing incidence of Corynebacterium group D2 strains resistant to norfloxacin and ciprofloxacin.
P2860
Q33649156-5B0CD857-F931-4CAE-82B2-904748F7EA3DQ33752287-ADA51A18-BCAD-4FA0-B31E-DFFA7971529BQ33982113-F1450C3C-2A9D-4E0D-BCE3-50EEFABA3DCEQ34729771-1E54C066-63CA-4648-ACCF-A48D8CB032FDQ35111896-0EAF5588-CCEA-418F-8E26-DE776CADAD03Q35122412-E5F84274-5782-41E1-BF87-214ECF683C18Q35270414-B9C6256A-2D66-46EA-9878-7E211D20ED51Q35329740-11CA7E5C-5B2F-4E25-83F5-62BADBE63F9AQ35821472-3BCB0237-489F-4B4C-BDBC-FDC25BD5B428Q35894550-DEF1A9FD-55DF-4070-AC5E-FB858FCDAC47Q35900349-237F7372-8BB3-4EE0-AB02-843CFF6A783AQ36752823-3719DA7D-F495-4B95-B7AD-A1851C3C8A1EQ36754434-6152E6B4-F5B1-4FA7-9291-9694BD146DE0Q36754888-943A5A3B-70ED-4678-8265-758CE79ED5D1Q37299512-175462CB-E2E4-4A57-8E57-EA9D60B981BDQ37834318-0A60B67C-B90F-4941-80E2-96B0A26A6803Q38113689-9CC0E9AD-15E3-4669-B7C2-F4476230B94BQ38322827-7808A998-6C5F-4899-B97F-8892C8CB9E15Q38408892-A570EA3D-033D-41DD-90D6-7A3E8D36DCA8Q39819300-E8A3F981-4BB8-4F05-BC20-350D54CBF628Q40633555-445C42AC-5C06-4404-B6E3-8690423F35DDQ40903054-F65EF05C-420A-4054-9F5A-2B7B869DC332Q43986465-8EEF70E3-2C4D-48C0-8534-D8C4F11878FCQ44073055-21ED2CDF-4BE0-4F48-8AC0-D349028CE380Q44700233-C716CBD4-1DFA-4FFC-A142-4753320F48F9Q46523757-415E88D7-4611-4C63-B56B-EAB374D6C304Q50154504-9642A679-DC78-4F60-9E53-1A3CC2BF8539Q54221191-FA015C35-CED7-48E5-8253-B5454740C7C6Q54227945-405ED132-4282-483F-9ACE-0B6EC1FE0530Q54263112-DA375E8A-B629-4D30-8269-08A81B537294Q54339664-33D7F009-34AC-4F36-9DE5-55A1AC038D87
P2860
Development of resistance to nalidixic acid and the fluoroquinolones after the introduction of norfloxacin and ofloxacin
description
1988 nî lūn-bûn
@nan
1988 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1988 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
name
Development of resistance to n ...... n of norfloxacin and ofloxacin
@ast
Development of resistance to n ...... n of norfloxacin and ofloxacin
@en
type
label
Development of resistance to n ...... n of norfloxacin and ofloxacin
@ast
Development of resistance to n ...... n of norfloxacin and ofloxacin
@en
prefLabel
Development of resistance to n ...... n of norfloxacin and ofloxacin
@ast
Development of resistance to n ...... n of norfloxacin and ofloxacin
@en
P2860
P356
P1476
Development of resistance to n ...... n of norfloxacin and ofloxacin
@en
P2093
Wiedemann B
P2860
P304
P356
10.1128/AAC.32.8.1285
P407
P577
1988-08-01T00:00:00Z